New data presented at ECCMID confirms that QuickMIC® outputs accurate AST results in record time
Gradientech today announces that the recently presented abstract “A multi-center evaluation of a novel microfluidic rapid AST assay for Gram-negative bloodstream infections” concludes that its ultra-rapid and precise diagnostic system QuickMIC® can be used to determine antibiotic susceptibility and measure precise linear MIC (Minimum Inhibitory Concentration) values with very high accuracy, with time to result hours faster than competing AST (Antibiotic Susceptibility Testing) systems.
The European multi-center study was presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Copenhagen, Denmark. The study was conducted at University Hospital Örebro and University Hospital Uppsala in Sweden and University Medical Center Hamburg-Eppendorf in Germany and at Gradientech.
“It is encouraging to present clinical data that confirms the strong features and value of our QuickMIC system. To rapidly understand what antibiotics that works for the individual sepsis patient can mean the difference between life and death. I´m also very happy to see all the professional engagement from our study sites. Strong commitment is essential for implementing next generation AST in clinical practice”, says Sara Thorslund, CEO of Gradientech.
The data presented at ECCMID formed the basis for the CE-marking of the QuickMIC system and its Gram- Negative panel last year. The study included 560 tested bacteria strains of which 148 consecutive clinical samples. Notably the study included a challenging set-up with more than 30% of the bacteria strains being resistant to more than three antibiotic classes.
In conclusion results show that the QuickMIC system performs well above regulatory requirements (Essential Agreement of 95.4% and Categorical Agreement of 95.6%, compared to regulatory requirement of at least 90.0%) and is confirmed to be the fastest phenotypic AST system for positive blood cultures on the market today (average of 3 hours and 18 minutes time to result for all 5,268 antibiotic-bacteria combinations in the study).
The QuickMIC system and its Gram-negative panel are CE-marked and commercially available in Europe but not FDA 510(k)-cleared and not available for sale in the United States.
For further information, please contact:
Sara Thorslund, PhD, CEO Gradientech
Tel: +46 736 29 35 80
Gradientech is leading the field of ultra-rapid antibiotic susceptibility testing. We develop next-generation diagnostics in infectious disease medicine. Our product QuickMIC® allows patients with sepsis to quickly receive specific guidance on the right antibiotic in the right dose. It saves lives, reduces healthcare costs and limits the spread of antibiotic resistance – one of the greatest global health threats of our time. Gradientech is headquartered in Uppsala. Visit www.gradientech.se for more information.
Documents230426 New QuickMIC data confirms
Next-generation antimicrobial susceptibility testingTake a look at our E-book